Cogent Biosciences Inc To Discuss Lead-In GIST Data at ASCO from the Ongoing PEAK Phase 3 Trial Evaluating Bezuclastinib in Combination with Sunitinib Call Transcript - Thomson StreetEvents

Cogent Biosciences Inc To Discuss Lead-In GIST Data at ASCO from the Ongoing PEAK Phase 3 Trial Evaluating Bezuclastinib in Combination with Sunitinib Call Transcript

Cogent Biosciences Inc To Discuss Lead-In GIST Data at ASCO from the Ongoing PEAK Phase 3 Trial Evaluating Bezuclastinib in Combination with Sunitinib Call Transcript - Thomson StreetEvents
Cogent Biosciences Inc To Discuss Lead-In GIST Data at ASCO from the Ongoing PEAK Phase 3 Trial Evaluating Bezuclastinib in Combination with Sunitinib Call Transcript
Published Jun 05, 2023
Published Jun 05, 2023
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of COGT.OQ conference call or presentation 5-Jun-23 12:00pm GMT

  
Report Type:

Transcript

Source:
Company:
Cogent Biosciences Inc
Ticker
COGT.OQ
Time
12:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

Cogent Biosciences Inc at JPMorgan Healthcare Conference Transcript – 2025-01-14 – US$ 54.00 – Edited Transcript of COGT.OQ presentation 14-Jan-25 3:30pm GMT

Cogent Biosciences Inc To Host Data Release Call Transcript – 2024-12-09 – US$ 54.00 – Edited Transcript of COGT.OQ conference call or presentation 9-Dec-24 1:00pm GMT

Cogent Biosciences Inc Annual Shareholders Meeting Transcript – 2024-06-05 – US$ 54.00 – Edited Transcript of COGT.OQ shareholder or annual meeting 5-Jun-24 1:00pm GMT

Cogent Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript – 2023-09-13 – US$ 54.00 – Edited Transcript of COGT.OQ presentation 13-Sep-23 12:10pm GMT

Cogent Biosciences Inc at Jefferies Healthcare Conference Transcript – 2023-06-08 – US$ 54.00 – Edited Transcript of COGT.OQ presentation 8-Jun-23 1:30pm GMT

Cogent Biosciences Inc at Stifel Targeted Oncology Days (Virtual) Transcript – 2023-04-25 – US$ 54.00 – Edited Transcript of COGT.OQ presentation 25-Apr-23 4:30pm GMT

Cogent Biosciences Inc at Needham Healthcare Conference (Virtual) Transcript – 2023-04-19 – US$ 54.00 – Edited Transcript of COGT.OQ presentation 19-Apr-23 6:15pm GMT

Cogent Biosciences Inc at JPMorgan Healthcare Conference Transcript – 2023-01-12 – US$ 54.00 – Edited Transcript of COGT.OQ presentation 12-Jan-23 3:30pm GMT

Cogent Biosciences Inc To Discuss Updated APEX Trial Phase 2 Data at ASH Call Transcript – 2022-12-12 – US$ 54.00 – Edited Transcript of COGT.OQ conference call or presentation 12-Dec-22 1:00pm GMT

Cogent Biosciences Inc To Discuss Initial Clinical Data presented At the European Hematology Association Congress Call Transcript – 2022-06-10 – US$ 54.00 – Edited Transcript of COGT.OQ conference call or presentation 10-Jun-22 12:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Cogent Biosciences Inc To Discuss Lead-In GIST Data at ASCO from the Ongoing PEAK Phase 3 Trial Evaluating Bezuclastinib in Combination with Sunitinib Call Transcript" Jun 05, 2023. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Cogent-Biosciences-Inc-To-Discuss-Lead-In-GIST-Data-at-ASCO-from-the-Ongoing-PEAK-Phase-3-Trial-Evaluating-Bezuclastinib-in-Combination-with-Sunitinib-Call-T15609580>
  
APA:
Thomson StreetEvents. (2023). Cogent Biosciences Inc To Discuss Lead-In GIST Data at ASCO from the Ongoing PEAK Phase 3 Trial Evaluating Bezuclastinib in Combination with Sunitinib Call Transcript Jun 05, 2023. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Cogent-Biosciences-Inc-To-Discuss-Lead-In-GIST-Data-at-ASCO-from-the-Ongoing-PEAK-Phase-3-Trial-Evaluating-Bezuclastinib-in-Combination-with-Sunitinib-Call-T15609580>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.